Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects

NCT03430999 is registered in ClinicalTrials.gov with Egetis Therapeutics as lead sponsor.

NCT NCT03430999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects
Lead sponsor
Egetis Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
November 7, 2017
Completion date
December 18, 2017
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn)